<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430661</url>
  </required_header>
  <id_info>
    <org_study_id>ID-076-103</org_study_id>
    <nct_id>NCT03430661</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects</brief_title>
  <official_title>Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel, Prasugrel, and Ticagrelor), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or, Prasugrel, or Ticagrelor When Administered After a Single Subcutaneous Dose of the P2Y12 Antagonist ACT-246475 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the pharmacodynamic (PD) effects of&#xD;
      clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.)&#xD;
      dose of ACT-246475 in healthy male and female subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Actual">May 29, 2019</completion_date>
  <primary_completion_date type="Actual">May 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-matched comparisons of IPA% (MPA) between treatments (i.e., Treatment A1 vs A2, Treatment B1 vs B2, and treatment C1 vs C2, treatments are defined below) following administration of ACT-246475 and its matching placebo.</measure>
    <time_frame>From baseline up to 48 hours</time_frame>
    <description>- IPA%[MPA] will be calculated as mean change in percentage from baseline for each time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-matched comparisons of IPA %(PRU) between treatments (i.e., Treatment A1 vs A2, Treatment B1 vs B2, and treatment C1 vs C2) following administration of ACT-246475 and its matching placebo.</measure>
    <time_frame>From baseline up to 48 hours</time_frame>
    <description>- IPA%[PRU] will be calculated as mean change in percentage from baseline for each time point.&#xD;
Treatment A1: single s.c. dose administration of ACT-246475-matching placebo followed by a single oral dose of clopidogrel (600 mg).&#xD;
Treatment A2: single s.c. dose administration (16 mg) of ACT-246475 followed by a single oral dose of clopidogrel (300 mg).&#xD;
Treatment B1: single s.c. dose administration of ACT-246475-matching placebo followed by a single oral dose of prasugrel (60 mg).&#xD;
Treatment B2: single s.c. dose administration (16 mg) of ACT-246475 followed by a single oral dose of prasugrel (60 mg).&#xD;
Treatment C1: single s.c. dose administration of ACT-246475-matching placebo followed by a single oral dose of ticagrelor (180 mg).&#xD;
Treatment B2: single s.c. dose administration (16 mg) of ACT-246475 followed by a single oral dose of ticagrelor (180 mg).</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel will be administered 12 h after ACT-246475 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any time interval up to 24 h between the administration of ACT-246475 or placebo and clopidogrel may be studied</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel will be administered 12 h after ACT-246475 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-246475</intervention_name>
    <description>Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection</description>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_label>Part A: Group 3</arm_group_label>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3</arm_group_label>
    <arm_group_label>Part C: Group 1</arm_group_label>
    <arm_group_label>Part C: Group 2</arm_group_label>
    <arm_group_label>Part C: Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Tablet for oral administration (300 or 600 mg)</description>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_label>Part A: Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Tablet for oral administration (60 mg)</description>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution</description>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_label>Part A: Group 3</arm_group_label>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3</arm_group_label>
    <arm_group_label>Part C: Group 1</arm_group_label>
    <arm_group_label>Part C: Group 2</arm_group_label>
    <arm_group_label>Part C: Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Tablet for oral administration (180 mg)</description>
    <arm_group_label>Part C: Group 1</arm_group_label>
    <arm_group_label>Part C: Group 2</arm_group_label>
    <arm_group_label>Part C: Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Healthy male and female subjects aged between 18 and 65 years (inclusive) at screening&#xD;
&#xD;
          -  Body mass index of 18.0 to 31.0 kg/m2 (inclusive) at Screening&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test and use&#xD;
             reliable birth controls from screening up to at least 30 days after last study&#xD;
             treatment administration&#xD;
&#xD;
          -  Systolic blood pressure (SBP) 100-140 mmHg, diastolic blood pressure (DBP) 50-90 mmHg,&#xD;
             and pulse rate 50-90 beats per minute (bpm) (inclusive) at screening&#xD;
&#xD;
          -  Healthy on the basis of physical examination, cardiovascular assessments, and&#xD;
             laboratory tests&#xD;
&#xD;
          -  Maximum (at peak) platelet aggregation ≥ 40% (light transmission aggregometry [LTA])&#xD;
             upon 20 μM adenosine diphosphate (ADP) activation at screening&#xD;
&#xD;
          -  Values of closure time tested with the Platelet Function Analyzer (PFA) equipment, for&#xD;
             both cartridges of collagen/adrenaline and collagen/ADP below the upper limit of&#xD;
             normal range at screening&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Known hypersensitivity to ACT-246475, clopidogrel, prasugrel, ticagrelor, any of their&#xD;
             excipients, or drugs of the same class&#xD;
&#xD;
          -  Any contraindication to clopidogrel, prasugrel, or ticagrelor treatment&#xD;
&#xD;
          -  Known hypersensitivity or allergy to natural rubber latex&#xD;
&#xD;
          -  Platelet count &lt; 120 × 109 L-1 at Screening and Day -1&#xD;
&#xD;
          -  Known platelet disorders (e.g., Glanzmann thromboasthenia, von Willebrand disease,&#xD;
             platelet release defect)&#xD;
&#xD;
          -  Previous treatment with acetylsalicylate, non-steroidal anti-inflammatory drugs, P2Y12&#xD;
             receptor antagonists, or any medication with blood-thinning activity (i.e., injectable&#xD;
             or oral anticoagulants) within 3 weeks prior to study treatment administration&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biotrial Inc</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Schilling U, Dingemanse J, Dobrow M, Baumann M, Riederer MA, Juif PE, Ufer M. Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. Thromb Haemost. 2021 Jun;121(6):755-766. doi: 10.1055/s-0040-1721773. Epub 2021 Jan 7.</citation>
    <PMID>33412611</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

